Greenwich LifeSciences Inc. (NASDAQ:GLSI)
Bands
Volume
200 SMA
50 SMA
20 SMA
Videos
Alerts
Articles
Events
Old Forum Content for GLSI
Make a Forum Post Become a member to view recent forum posts. Already a member? Sign in here.
- woodman: $GLSI has been moving very well the last few weeks. Folks in this one have been waiting for data for its breast cancer add-on med for Herceptin for quite some time. Makes me wonder....
- DavidK: $GLSI- someone mentioned this a few days ago . I bought some . Moving up
- woodman: $GLSI - Added to GLSI earlier in the day. It moved well. It will probably be my last add, though I've said that before. I've been accumulating from low $13s to mid $14s, though today's buy at $15.75 was outside this range. I'm still *hoping* for a nice pop when it officially becomes a member of the Russell 2k/3k and has to be bought by funds on Friday (at market close, I believe) It's a low floater so it could move well, and probably is low short term risk in the area of where I've been accumulating. I plan to sell on any significant pop. Looking at the chart, I could see a move to $20-$22.
- woodman: #Russell 1000, 2000 and 3000 will undergo rebalancing on June 28. Institutions will have to buy and sell. There could be some some movers. I've purchased low floater biotech $GLSI as one that I think (hope? :-0 ) will move decently, but we'll see. https://www.bankrate.com/investing/russell-index-rebalancing/#:~:text=On%20June%2028th%2C%202024%2C%20the,indexes%2C%20impacting%20hundreds%20of%20stocks.
- woodman: $GLSI - my volatile tiny floater is breaking out and now back up through $16. I've been collecting it in the low $13s to the mid $14s. I'm thinking $20-plus by month's end with coming Russell inclusion (6/28) as wind in the sails.
- mopick: @woodman $GLSI, CEO purchased 174,825 shares on June 13.
- woodman: @mopick $GLSI - Yes. It's an odd operation over there, but he's been a continual buyer of the stock. I never previously saw him buy that much at one time, however.
- MongosPawn: $GLSI Nice call Woodman!
- woodman: @MongosPawn $GLSI - Thanks, but $CLRB getting hit on $MBIO news. The gods giveth and they taketh away.
-
woodman: ...
$GLSI - End of June inclusion into Russell 2K/3k. Potential decent move for this small float stock. I'm likely at the spot of where I want to be with my position at this point, though may add a little more at the right price.
$HUMA - It's chillin' ... - woodman: @woodman $CLRB $GLSI $HUMA $ARDX $VKTX #Biotech #Radiopharma. Oops, I forgot $MREO. $MREO had impressive data the other day for its setrusumab (partnered with $RARE for Osteogenesis Imperfecta - brittle bones). It's hard to buy on the chart right now, but I do think this is one to be in. My position, unfortunately, is small. I wish I had more. PTs were raised to $7 and $8 on the news. It has moved from $3.50 to $4.25 since reporting.
- MongosPawn: @woodman $CLRB $GLSI $HUMA $ARDX $VKTX #Biotech #Radiopharma Great stuff as usual. Thanks. Have a great weekend.
- woodman: @woodman $CLRB $GLSI $HUMA $ARDX $VKTX #Biotech #Radiopharma - One more edit. I wrote: " i.e. it is likely it will have to do a Phase 2b trial and can't skip straight to a Phase 2 for...." That "Phase 2" at the end of my quote should say Phase 3 (not Phase 2).
- sierramp: @woodman $CLRB $GLSI $HUMA $ARDX $VKTX #Biotech #Radiopharma Thanks as always woodman.
-
woodman: ...
I have condensed my biotech holdings considerably. I currently have $ARDX $VKTX $CLRB and $HUMA (with intermediate or longer term views), a small position in $MREO, and also a decent position in $GLSI for its coming inclusion in the Russell 2k/3k. I ... - woodman: @dgrobo $CRWD $KKR - Fwiw, I'm in an under-the-radar little one - $GLSI (working on a breast cancer med) - that I hope moves decently with its coming inclusion in the Russell 3k/2K. https://www.lseg.com/content/dam/ftse-russell/en_us/documents/other/ru3000-additions-preliminary-20240524.pdf
- woodman: #Biotech - Summer months with no help from the fed on rates makes biotech a difficult place to be, though many do have catalyts coming possibly in June/summer. That said, I have reduced the number of biotechs I am holding. I currently hold $VKTX $ARDX $HUMA (credit to @Mikev200 for HUMA) $CLRB and $GLSI. Some are testing my patience but I do have a rationale and plan for each of these. These aren't chart trades. Just an fyi for any interested biotechies here.
- woodman: $VKTX $ARDX $CLRB $GLSI $XFOR $EFTR $MREO $INZY $PDSB $NWBO - delete "Primary" - should just say Biotech positions....
- woodman: Primary Biotech positions in order of size: $VKTX (largest - overweight, pardon the pun) $ARDX (large) $CLRB (mid-size) $GLSI (mid-small) $XFOR (small) $EFTR (small). All others essentially placeholders or very small - $MREO $INZY $PDSB. Finally, I just bought huge bioturd $NWBO, which I can't in good conscience recommend, but I believe will have its glioblastoma vax approved in the UK between now and July. The company and management is a disaster, and I doubt they will be able to large scale commercialize it if approved, but I think upon approval it could double or triple, then will be sold into immediately, which would be my plan. But make no mistake, I think the company sucks. After years of watching the cult faithfuls who follow it, I think there are plenty of lemmings to sell off of.
- DBones808: $GLSI sitting on the 50....let's see what happens
- DBones808: $GLSI on watch, 50 day is inbound, been basing for 3 months
- Nepenthe: $GLSI, "squeezing" but highly speculative. Don't know if I have the requisite adrenaline for this one. Cheers.
- Bwhitty: $GLSI interesting here but dangerous. PB to bands at 54. Near 12/09 close 57.10. VWAP 57.9 VMA 55. A bunch of numbers tight on a stock that went from 12.15 to 158!
- Jim88: @Bwhitty $GLSI You might be better off betting the favorite in the first at Aqueduct. 7F on the dirt. Maiden Claimers.
- scottrades: Anyone own $GLSI?
- Bwhitty: @scottrades $GLSI Why you want them to take you to dinner 😁😁
- scottrades: @Bwhitty $GLSI Getting my Christmas card list together! :)
- Bwhitty: @scottrades $GLSI Right! I don't post in here because its not the place. But I have been buying pennies stocks, sell half when they double and hold the rest for free. They go to 0 you didn't loose a dollar but sometimes, sometimes .01 goes to a dollars. And those are nice.
- romanalexk: @Bwhitty $GLSI Dear Santa I would like a lambo, pony and a trip to Hawaii
- Auto: @Bwhitty $GLSI yes $RIOT $CTIC working well 8>)
- Angdionk: $GLSI lol...my son bought this earlier
- JosephM: $GLSI..the ones that got in are the ones that got the news and jumped on it. How do we get the news? Kaplan Meier analysis of disease free survival for patients treated with GP2 immunotherapy shows 100% survival (0% breast cancer recurrences, p = 0.0338) following surgery and Herceptin treatment over median 5 years of follow-up
- nakedtrader: $GLSI Now that's a pop
- Bwhitty: @nakedtrader $GLSI I have been watching it but not early enough to play, haulted so many times.
- tommymac: @nakedtrader $GLSI I should say so!!!
- Hokie54: anybody in $GLSI besides me?
- Bwhitty: @Hokie54 $GLSI Be careful 😁
- Angdionk: @Bwhitty $GLSI my son was I'm not sure if he still is he said he was going to take profits think he got in around 40. He is in the navy and at work now so I dont know but think he sold before he went into work
- Docoof:
- Herb: @nakedtrader $GLSI WTF?
- Docoof:
- tommymac: @Hokie54 $GLSI how about a loan?
- tommymac: @Hokie54 $GLSI What the heck happened anyway did they come up with a cure for cancer???
| Stock Price | $20.57 |
| Change | 19.53% |
| Volume | 1,254,700 |
Greenwich LifeSciences Inc is a clinical stage bio-pharmaceutical company focused on the development of an immunotherapy to prevent breast cancer recurrences in patients.
Request Video of GLSIAlready a member? Sign in here.
Past Month
Leading Peers
-
$29.66 174.42%
-
$20.57 90.15%
-
$17.77 84.02%
Past Month
Lagging Peers
-
$14.25 -88.97%
-
$44.58 -38.77%
-
$8.24 -36.06%
Dan Fitzpatrick
Stock Market Mentor gives you EVERYTHING you need to succeed in the market; all in one place. How easy is that? Dan Fitzpatrick and his elite community of traders share trading ideas, strategies and much more. Dan Fitzpatrick--a world class Technical Analyst, trading coach and regular CNBC contributor--gives you access to all of this with a 30 day trial membership for just $7.77. Get started TODAY and start trading better TOMORROW with the following premium content:
- Nightly video Strategy Sessions with a game plan for tomorrow
- Got a stock you want Dan to look at? Just ask.
- Patent pending video alerts instantly delivered to you when one of Dan’s trading signals is triggered. This is not your typical price alert. This is a short video explaining the action you need to take to make money. No more “Woulda, coulda, shoulda”
- Access to over 90,400 stock analysis videos
- Access an ever expanding library (90,400) of educational videos that will save you time and make you money
Join a team of friends and traders that have one thing in common; a burning desire to succeed.
Become a Member Today!
Gain immediate access to all our exclusive articles, features, how-to's, discussion group and much more...
Satisfaction Guaranteed!
Your Stock Market Mentor membership comes with a 30 day, no questions asked, 100% money back guarantee!